Format

Send to

Choose Destination
Future Med Chem. 2013 Apr;5(5):553-72. doi: 10.4155/fmc.13.17.

Hypoxia inducible factor pathway inhibitors as anticancer therapeutics.

Author information

1
Department of Chemistry & Center for Diagnostics & Therapeutics, Georgia State University, Room 313, Petit Science Center, 100 Piedmont Ave, Atlanta, GA, 30303-3083, USA.
2
Departments of Neurosurgery and Hematology & Medical Oncology, School of Medicine and Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA.
#
Contributed equally

Abstract

Hypoxia is a significant feature of solid tumor cancers. Hypoxia leads to a more malignant phenotype that is resistant to chemotherapy and radiation, is more invasive and has greater metastatic potential. Hypoxia activates the hypoxia inducible factor (HIF) pathway, which mediates the biological effects of hypoxia in tissues. The HIF complex acts as a transcription factor for many genes that increase tumor survival and proliferation. To date, many HIF pathway inhibitors indirectly affect HIF but there have been no clinically approved direct HIF inhibitors. This can be attributed to the complexity of the HIF pathway, as well as to the challenges of inhibiting protein-protein interactions.

PMID:
23573973
PMCID:
PMC3871878
DOI:
10.4155/fmc.13.17
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center